Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor indicated for the treatment of severe chronic obstructive pulmonary disease (COPD) to reduce the risk of exacerbations. This category provides… Read more




































Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor indicated for the treatment of severe chronic obstructive pulmonary disease (COPD) to reduce the risk of exacerbations. This category provides a comprehensive selection of Roflumilast reference standards, including the active pharmaceutical ingredient, process-related impurities, synthetic intermediates, and degradation products. These high-quality materials are essential for pharmaceutical laboratories performing rigorous impurity profiling and analytical method validation. Furthermore, the inclusion of stable isotope labelled compounds serves as critical internal standards for accurate quantification in complex matrices during bioanalytical and stability testing. By utilizing these well-characterized standards, laboratories can ensure robust quality control and regulatory compliance throughout the drug development and manufacturing lifecycle, supporting precise identification and qualification of unknown peaks in compliance with established pharmacopeial guidelines.